1 Market Overview

1.1 Product Overview and Scope of Nucleic Acid-based Drugs

1.2 Classification of Nucleic Acid-based Drugs by Type

1.2.1 Overview: Global Nucleic Acid-based Drugs Market Size by Type: 2022 Versus 2028

1.2.2 Global Nucleic Acid-based Drugs Revenue Market Share by Type in 2029

1.2.3 ASO

1.2.4 mRNA

1.2.5 siRNA

1.2.6 miRNA

1.2.7 saRNA

1.2.8 Aptamer

1.3 Global Nucleic Acid-based Drugs Market by Application

1.3.1 Overview: Global Nucleic Acid-based Drugs Market Size by Application: 2023 Versus 2029

1.3.2 Genetic Disease

1.3.3 Cancer

1.3.4 Cardiovascular Diseases

1.3.5 Other

1.4 Global Nucleic Acid-based Drugs Market Size & Forecast

1.5 Market Drivers, Restraints and Trends

1.5.1 Nucleic Acid-based Drugs Market Drivers

1.5.2 Nucleic Acid-based Drugs Market Restraints

1.5.3 Nucleic Acid-based Drugs Trends Analysis

2 Company Profiles

2.1 Ionis Pharmaceuticals

2.1.1 Ionis Pharmaceuticals Details

2.1.2 Ionis Pharmaceuticals Major Business

2.1.3 Ionis Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions

2.1.4 Ionis Pharmaceuticals Recent Developments and Future Plans

2.2 Sarepta Therapeutics

2.2.1 Sarepta Therapeutics Details

2.2.2 Sarepta Therapeutics Major Business

2.2.3 Sarepta Therapeutics Nucleic Acid-based Drugs Product and Solutions

2.2.4 Sarepta Therapeutics Recent Developments and Future Plans

2.3 Nippon Shinyaku

2.3.1 Nippon Shinyaku Details

2.3.2 Nippon Shinyaku Major Business

2.3.3 Nippon Shinyaku Nucleic Acid-based Drugs Product and Solutions

2.3.4 Nippon Shinyaku Recent Developments and Future Plans

2.4 BioNTech

2.4.1 BioNTech Details

2.4.2 BioNTech Major Business

2.4.3 BioNTech Nucleic Acid-based Drugs Product and Solutions

2.4.4 BioNTech Recent Developments and Future Plans

2.5 Moderna Therapeutics

2.5.1 Moderna Therapeutics Details

2.5.2 Moderna Therapeutics Major Business

2.5.3 Moderna Therapeutics Nucleic Acid-based Drugs Product and Solutions

2.5.4 Moderna Therapeutics Recent Developments and Future Plans

2.6 CureVac

2.6.1 CureVac Details

2.6.2 CureVac Major Business

2.6.3 CureVac Nucleic Acid-based Drugs Product and Solutions

2.6.4 CureVac Recent Developments and Future Plans

2.7 Alnylam Pharmaceuticals

2.7.1 Alnylam Pharmaceuticals Details

2.7.2 Alnylam Pharmaceuticals Major Business

2.7.3 Alnylam Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions

2.7.4 Alnylam Pharmaceuticals Recent Developments and Future Plans

2.8 Regulus Therapeutics

2.8.1 Regulus Therapeutics Details

2.8.2 Regulus Therapeutics Major Business

2.8.3 Regulus Therapeutics Nucleic Acid-based Drugs Product and Solutions

2.8.4 Regulus Therapeutics Recent Developments and Future Plans

2.9 Miragen Therapeutics

2.9.1 Miragen Therapeutics Details

2.9.2 Miragen Therapeutics Major Business

2.9.3 Miragen Therapeutics Nucleic Acid-based Drugs Product and Solutions

2.9.4 Miragen Therapeutics Recent Developments and Future Plans

2.10 Mina Therapeutics

2.10.1 Mina Therapeutics Details

2.10.2 Mina Therapeutics Major Business

2.10.3 Mina Therapeutics Nucleic Acid-based Drugs Product and Solutions

2.10.4 Mina Therapeutics Recent Developments and Future Plans

2.11 NeXstar Pharmaceuticals

2.11.1 NeXstar Pharmaceuticals Details

2.11.2 NeXstar Pharmaceuticals Major Business

2.11.3 NeXstar Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions

2.11.4 NeXstar Pharmaceuticals Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Nucleic Acid-based Drugs Revenue and Share by Players (2023 & 2029)

3.2 Nucleic Acid-based Drugs Players Head Office, Products and Services Provided

3.3 Nucleic Acid-based Drugs Mergers & Acquisitions

3.4 Nucleic Acid-based Drugs New Entrants and Expansion Plans

4 Global Nucleic Acid-based Drugs Forecast by Region

4.1 Global Nucleic Acid-based Drugs Market Size by Region: 2023 VS 2029

4.2 Global Nucleic Acid-based Drugs Market Size by Region, (2023-2029)

4.3 North America

4.3.1 Key Companies of Nucleic Acid-based Drugs in North America

4.3.2 Current Situation and Forecast of Nucleic Acid-based Drugs in North America

4.3.3 North America Nucleic Acid-based Drugs Market Size and Prospect (2023-2029)

4.4 Europe

4.4.1 Key Companies of Nucleic Acid-based Drugs in Europe

4.4.2 Current Situation and Forecast of Nucleic Acid-based Drugs in Europe

4.4.3 Europe Nucleic Acid-based Drugs Market Size and Prospect (2023-2029)

4.5 Asia-Pacific

4.5.1 Key Companies of Nucleic Acid-based Drugs in Asia-Pacific

4.5.2 Current Situation and Forecast of Nucleic Acid-based Drugs in Asia-Pacific

4.5.3 Asia-Pacific Nucleic Acid-based Drugs Market Size and Prospect (2023-2029)

4.5.4 China

4.5.5 Japan

4.5.6 South Korea

4.6 South America

4.6.1 Key Companies of Nucleic Acid-based Drugs in South America

4.6.2 Current Situation and Forecast of Nucleic Acid-based Drugs in South America

4.6.3 South America Nucleic Acid-based Drugs Market Size and Prospect (2023-2029)

4.7 Middle East & Africa

4.7.1 Key Companies of Nucleic Acid-based Drugs in Middle East & Africa

4.7.2 Current Situation and Forecast of Nucleic Acid-based Drugs in Middle East & Africa

4.7.3 Middle East & Africa Nucleic Acid-based Drugs Market Size and Prospect (2023-2029)

5 Market Size Segment by Type

5.1 Global Nucleic Acid-based Drugs Market Forecast by Type (2023-2029)

5.2 Global Nucleic Acid-based Drugs Market Share Forecast by Type (2023-2029)

6 Market Size Segment by Application

6.1 Global Nucleic Acid-based Drugs Market Forecast by Application (2023-2029)

6.2 Global Nucleic Acid-based Drugs Market Share Forecast by Application (2023-2029)

7 Research Findings and Conclusion

8 Appendix

8.1 Methodology

8.2 Research Process and Data Source

8.3 Disclaimer

List of Tables

Table 1. Global Nucleic Acid-based Drugs Revenue by Type, (USD Million), 2023 VS 2029

Table 2. Global Nucleic Acid-based Drugs Revenue by Application, (USD Million), 2023 VS 2029

Table 3. Ionis Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 4. Ionis Pharmaceuticals Major Business

Table 5. Ionis Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions

Table 6. Sarepta Therapeutics Corporate Information, Head Office, and Major Competitors

Table 7. Sarepta Therapeutics Major Business

Table 8. Sarepta Therapeutics Nucleic Acid-based Drugs Product and Solutions

Table 9. Nippon Shinyaku Corporate Information, Head Office, and Major Competitors

Table 10. Nippon Shinyaku Major Business

Table 11. Nippon Shinyaku Nucleic Acid-based Drugs Product and Solutions

Table 12. BioNTech Corporate Information, Head Office, and Major Competitors

Table 13. BioNTech Major Business

Table 14. BioNTech Nucleic Acid-based Drugs Product and Solutions

Table 15. Moderna Therapeutics Corporate Information, Head Office, and Major Competitors

Table 16. Moderna Therapeutics Major Business

Table 17. Moderna Therapeutics Nucleic Acid-based Drugs Product and Solutions

Table 18. CureVac Corporate Information, Head Office, and Major Competitors

Table 19. CureVac Major Business

Table 20. CureVac Nucleic Acid-based Drugs Product and Solutions

Table 21. Alnylam Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 22. Alnylam Pharmaceuticals Major Business

Table 23. Alnylam Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions

Table 24. Regulus Therapeutics Corporate Information, Head Office, and Major Competitors

Table 25. Regulus Therapeutics Major Business

Table 26. Regulus Therapeutics Nucleic Acid-based Drugs Product and Solutions

Table 27. Miragen Therapeutics Corporate Information, Head Office, and Major Competitors

Table 28. Miragen Therapeutics Major Business

Table 29. Miragen Therapeutics Nucleic Acid-based Drugs Product and Solutions

Table 30. Mina Therapeutics Corporate Information, Head Office, and Major Competitors

Table 31. Mina Therapeutics Major Business

Table 32. Mina Therapeutics Nucleic Acid-based Drugs Product and Solutions

Table 33. NeXstar Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 34. NeXstar Pharmaceuticals Major Business

Table 35. NeXstar Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions

Table 36. Global Nucleic Acid-based Drugs Revenue (USD Million) by Players (2023 & 2029)

Table 37. Global Nucleic Acid-based Drugs Revenue Share by Players (2023 & 2029)

Table 38. Nucleic Acid-based Drugs Players Head Office, Products and Services Provided

Table 39. Nucleic Acid-based Drugs Mergers & Acquisitions in the Past Five Years

Table 40. Nucleic Acid-based Drugs New Entrants and Expansion Plans

Table 41. Global Market Nucleic Acid-based Drugs Revenue (USD Million) Comparison by Region (2023 VS 2029)

Table 42. Global Nucleic Acid-based Drugs Revenue Market Share by Region (2023-2029)

Table 43. Key Companies of Nucleic Acid-based Drugs in North America

Table 44. Current Situation and Forecast of Nucleic Acid-based Drugs in North America

Table 45. Key Companies of Nucleic Acid-based Drugs in Europe

Table 46. Current Situation and Forecast of Nucleic Acid-based Drugs in Europe

Table 47. Key Companies of Nucleic Acid-based Drugs in Asia-Pacific

Table 48. Current Situation and Forecast of Nucleic Acid-based Drugs in Asia-Pacific

Table 49. Key Companies of Nucleic Acid-based Drugs in China

Table 50. Key Companies of Nucleic Acid-based Drugs in Japan

Table 51. Key Companies of Nucleic Acid-based Drugs in South Korea

Table 52. Key Companies of Nucleic Acid-based Drugs in South America

Table 53. Current Situation and Forecast of Nucleic Acid-based Drugs in South America

Table 54. Key Companies of Nucleic Acid-based Drugs in Middle East & Africa

Table 55. Current Situation and Forecast of Nucleic Acid-based Drugs in Middle East & Africa

Table 56. Global Nucleic Acid-based Drugs Revenue Forecast by Type (2023-2029)

Table 57. Global Nucleic Acid-based Drugs Revenue Forecast by Application (2023-2029)

List of Figures

Figure 1. Nucleic Acid-based Drugs Picture

Figure 2. Global Nucleic Acid-based Drugs Revenue Market Share by Type in 2029

Figure 3. ASO

Figure 4. mRNA

Figure 5. siRNA

Figure 6. miRNA

Figure 7. saRNA

Figure 8. Aptamer

Figure 9. Nucleic Acid-based Drugs Revenue Market Share by Application in 2029

Figure 10. Genetic Disease Picture

Figure 11. Cancer Picture

Figure 12. Cardiovascular Diseases Picture

Figure 13. Other Picture

Figure 14. Global Nucleic Acid-based Drugs Market Size, (USD Million): 2023 VS 2029

Figure 15. Global Nucleic Acid-based Drugs Revenue and Forecast (2023-2029) & (USD Million)

Figure 16. Nucleic Acid-based Drugs Market Drivers

Figure 17. Nucleic Acid-based Drugs Market Restraints

Figure 18. Nucleic Acid-based Drugs Market Trends

Figure 19. Ionis Pharmaceuticals Recent Developments and Future Plans

Figure 20. Sarepta Therapeutics Recent Developments and Future Plans

Figure 21. Nippon Shinyaku Recent Developments and Future Plans

Figure 22. BioNTech Recent Developments and Future Plans

Figure 23. Moderna Therapeutics Recent Developments and Future Plans

Figure 24. CureVac Recent Developments and Future Plans

Figure 25. Alnylam Pharmaceuticals Recent Developments and Future Plans

Figure 26. Regulus Therapeutics Recent Developments and Future Plans

Figure 27. Miragen Therapeutics Recent Developments and Future Plans

Figure 28. Mina Therapeutics Recent Developments and Future Plans

Figure 29. NeXstar Pharmaceuticals Recent Developments and Future Plans

Figure 30. Global Nucleic Acid-based Drugs Revenue Market Share by Region (2023-2029)

Figure 31. Global Nucleic Acid-based Drugs Revenue Market Share by Region in 2029

Figure 32. North America Nucleic Acid-based Drugs Revenue (USD Million) and Growth Rate (2023-2029)

Figure 33. Europe Nucleic Acid-based Drugs Revenue (USD Million) and Growth Rate (2023-2029)

Figure 34. Asia-Pacific Nucleic Acid-based Drugs Revenue (USD Million) and Growth Rate (2023-2029)

Figure 35. South America Nucleic Acid-based Drugs Revenue (USD Million) and Growth Rate (2023-2029)

Figure 36. Middle East & Africa Nucleic Acid-based Drugs Revenue (USD Million) and Growth Rate (2023-2029)

Figure 37. Global Nucleic Acid-based Drugs Market Share Forecast by Type (2023-2029)

Figure 38. Global Nucleic Acid-based Drugs Market Share Forecast by Application (2023-2029)

Figure 39. Methodology

Figure 40. Research Process and Data Source